PMID- 12167115
OWN - NLM
STAT- MEDLINE
DCOM- 20021202
LR  - 20191210
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 17
IP  - 9
DP  - 2002 Sep
TI  - Randomized comparative study of omeprazole and famotidine in reflux esophagitis.
PG  - 955-9
AB  - BACKGROUND: Although proton pump inhibitors (PPI) and H2-receptor antagonists 
      (H2-RA) are routinely used in the treatment of reflux esophagitis (RE), no 
      consensus has been reached yet as to whether the first-choice drug should be PPI 
      or H2-RA. In this study, the effects of omeprazole (OMP) and famotidine (FAM) on 
      RE have been examined in a randomized comparative study. METHODS: Protocols of 
      OMP 20 mg once daily or FAM 20 mg twice daily for 8 weeks were allocated to 56 
      cases with RE at random, using an envelope randomization method. Their efficacy 
      in achieving healing was examined endoscopically and a relief from subjective 
      symptoms was compared. RESULTS: Patient's background such as sex, age, 
      recurrence, hiatal hernia, smoking and drinking habits, and complications, and 
      the severity of esophagitis at the time of enrolment were not significantly 
      different between the two groups. Healing in the OMP group and the FAM group was 
      observed in 72 and 32% (P = 0.025) of patients at week 4 and 95 and 53% (P = 
      0.003) of patients at week 8, respectively. Subjective symptoms were relieved 
      more frequently in the OMP group (at week 2, 67% compared with 29%, P = 0.005; at 
      week 4, 95% compared with 55%, P = 0.009), but this superiority was not 
      significant at week 8 (94% compared with 65%, P = 0.085). No serious adverse 
      events occurred. CONCLUSIONS: Omeprazole provided quicker healing and a greater 
      relief from subjective symptoms than did FAM in the treatment of RE, and was 
      considered more suitable as a first-choice drug.
CI  - Copyright 2002 Blackwell Publishing Asia Pty Ltd
FAU - Kawano, Sunao
AU  - Kawano S
AD  - Department of Clinical Laboratory Science, School of Allied Health Sciences, 
      Faculty of Medicine, Osaka University, Japan. kawano@sahs.med.osaka-u.ac.jp
FAU - Murata, Hiroaki
AU  - Murata H
FAU - Tsuji, Shingo
AU  - Tsuji S
FAU - Kubo, Mitsuhiko
AU  - Kubo M
FAU - Tatsuta, Masaharu
AU  - Tatsuta M
FAU - Iishi, Hiroyasu
AU  - Iishi H
FAU - Kanda, Tsutomu
AU  - Kanda T
FAU - Sato, Tomonobu
AU  - Sato T
FAU - Yoshihara, Harumasa
AU  - Yoshihara H
FAU - Masuda, Eiji
AU  - Masuda E
FAU - Noguchi, Masahiko
AU  - Noguchi M
FAU - Kashio, Shinji
AU  - Kashio S
FAU - Ikeda, Masahiro
AU  - Ikeda M
FAU - Kaneko, Akira
AU  - Kaneko A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Histamine H2 Antagonists)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Aged
MH  - Drug Evaluation
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Esophagitis, Peptic/*drug therapy
MH  - Esophagoscopy
MH  - Famotidine/*therapeutic use
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/*therapeutic use
MH  - Prospective Studies
MH  - Random Allocation
MH  - Treatment Outcome
EDAT- 2002/08/09 10:00
MHDA- 2002/12/03 04:00
CRDT- 2002/08/09 10:00
PHST- 2002/08/09 10:00 [pubmed]
PHST- 2002/12/03 04:00 [medline]
PHST- 2002/08/09 10:00 [entrez]
AID - 2785 [pii]
AID - 10.1046/j.1440-1746.2002.02785.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2002 Sep;17(9):955-9. doi: 
      10.1046/j.1440-1746.2002.02785.x.